Hillman Capital Management Inc. Sells 6,846 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Hillman Capital Management Inc. lowered its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 13.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 45,969 shares of the medical equipment provider’s stock after selling 6,846 shares during the period. Zimmer Biomet comprises about 2.6% of Hillman Capital Management Inc.’s investment portfolio, making the stock its 17th biggest position. Hillman Capital Management Inc.’s holdings in Zimmer Biomet were worth $4,134,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBH. Gen Wealth Partners Inc bought a new position in shares of Zimmer Biomet during the 4th quarter valued at $31,000. Flagship Harbor Advisors LLC bought a new stake in Zimmer Biomet in the 4th quarter worth $32,000. Grove Bank & Trust grew its holdings in Zimmer Biomet by 431.6% in the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 328 shares during the last quarter. Cornerstone Financial Management LLC bought a new stake in Zimmer Biomet in the 4th quarter worth $37,000. Finally, Headlands Technologies LLC bought a new stake in Zimmer Biomet in the 2nd quarter worth $37,000. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ZBH shares. JPMorgan Chase & Co. cut their price target on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a report on Wednesday, April 29th. Wells Fargo & Company lowered their price target on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. Truist Financial reissued a “hold” rating and set a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, April 7th. Finally, Canaccord Genuity Group set a $83.00 target price on shares of Zimmer Biomet in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $102.70.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.28% of the stock is currently owned by insiders.

Zimmer Biomet Stock Performance

ZBH opened at $89.40 on Wednesday. The firm has a market cap of $17.29 billion, a P/E ratio of 23.22, a PEG ratio of 2.60 and a beta of 0.47. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29. The company has a 50 day simple moving average of $87.48 and a two-hundred day simple moving average of $90.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company’s revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.